These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 28275090)

  • 1. How I manage the toxicities of myeloma drugs.
    Delforge M; Ludwig H
    Blood; 2017 Apr; 129(17):2359-2367. PubMed ID: 28275090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pharmacologic management of multiple myeloma in older adults.
    Dempsey JL; Johns A; Rosko AE; Lazarus HM
    Expert Opin Pharmacother; 2019 May; 20(7):887-902. PubMed ID: 30785310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New Drugs in Multiple Myeloma.
    Kunacheewa C; Orlowski RZ
    Annu Rev Med; 2019 Jan; 70():521-547. PubMed ID: 30691369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma.
    Pantani L; Brioli A; Tacchetti P; Zannetti BA; Mancuso K; Rocchi S; Martello M; Rizzello I; Terragna C; Zamagni E; Cavo M
    Expert Rev Hematol; 2016 Mar; 9(3):315-23. PubMed ID: 26634945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How I treat the young patient with multiple myeloma.
    Gandolfi S; Prada CP; Richardson PG
    Blood; 2018 Sep; 132(11):1114-1124. PubMed ID: 29967130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel therapies for multiple myeloma.
    Wallington-Beddoe CT; Pitson SM
    Aging (Albany NY); 2017 Aug; 9(8):1857-1858. PubMed ID: 28854147
    [No Abstract]   [Full Text] [Related]  

  • 7. New pharmacotherapy options for multiple myeloma.
    Mina R; Cerrato C; Bernardini A; Aghemo E; Palumbo A
    Expert Opin Pharmacother; 2016; 17(2):181-92. PubMed ID: 26684262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteasome inhibitors for multiple myeloma.
    Okazuka K; Ishida T
    Jpn J Clin Oncol; 2018 Sep; 48(9):785-793. PubMed ID: 30102324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An update in treatment options for multiple myeloma in nontransplant eligible patients.
    Broijl A; Sonneveld P
    Expert Opin Pharmacother; 2015; 16(13):1945-57. PubMed ID: 26245702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of adverse events induced by next-generation immunomodulatory drug and proteasome inhibitors in multiple myeloma.
    Salvini M; Bonello F; Boccadoro M; Larocca A
    Expert Rev Anticancer Ther; 2017 Jan; 17(1):75-87. PubMed ID: 27894203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Navigating the treatment landscape in multiple myeloma: which combinations to use and when?
    Goldschmidt H; Ashcroft J; Szabo Z; Garderet L
    Ann Hematol; 2019 Jan; 98(1):1-18. PubMed ID: 30470875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance to proteasome inhibitors and other targeted therapies in myeloma.
    Wallington-Beddoe CT; Sobieraj-Teague M; Kuss BJ; Pitson SM
    Br J Haematol; 2018 Jul; 182(1):11-28. PubMed ID: 29676460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials.
    Usmani SZ; Nahi H; Plesner T; Weiss BM; Bahlis NJ; Belch A; Voorhees PM; Laubach JP; van de Donk NWCJ; Ahmadi T; Uhlar CM; Wang J; Feng H; Qi M; Richardson PG; Lonial S
    Lancet Haematol; 2020 Jun; 7(6):e447-e455. PubMed ID: 32470437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contemporary drug therapies for multiple myeloma.
    de la Puente P; Azab AK
    Drugs Today (Barc); 2013 Sep; 49(9):563-73. PubMed ID: 24086952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salvage therapy of multiple myeloma: the new generation drugs.
    Romano A; Conticello C; Cavalli M; Vetro C; Di Raimondo C; Di Martina V; Schinocca E; La Fauci A; Parrinello NL; Chiarenza A; Di Raimondo F
    Biomed Res Int; 2014; 2014():456037. PubMed ID: 24967371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How should we treat newly diagnosed multiple myeloma patients?
    Mateos MV; San Miguel JF
    Hematology Am Soc Hematol Educ Program; 2013; 2013():488-95. PubMed ID: 24319223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteasome inhibitors for the treatment of multiple myeloma.
    Scalzulli E; Grammatico S; Vozella F; Petrucci MT
    Expert Opin Pharmacother; 2018 Mar; 19(4):375-386. PubMed ID: 29478351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential or combination therapy for multiple myeloma.
    Nooka A; Lonial S
    Expert Rev Hematol; 2012 Oct; 5(5):533-45. PubMed ID: 23146057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Not Available].
    Hitz F
    Praxis (Bern 1994); 2016; 105(21):1255-1260. PubMed ID: 28573955
    [No Abstract]   [Full Text] [Related]  

  • 20. Immunomodulatory drugs in the treatment of multiple myeloma.
    Abe Y; Ishida T
    Jpn J Clin Oncol; 2019 Aug; 49(8):695-702. PubMed ID: 31187860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.